文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

CHHiP 试验:个体晚期直肠毒性终点的 α/β 比值估计

Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-01-04

基于 CHHiP 试验(前列腺癌根治性放疗 74Gy/37Fr、60Gy/20Fr、57Gy/19Fr 随机分组)的剂量学数据,采用 Lyman-Kutcher-Burman 模型按 6 类直肠晚期终点分别估计 α/β 比值。无剂量修正因子时各终点 α/β 估计自出血 1.6 Gy 至括约肌控制 3.1 Gy,频率加权平均 G1+ 为 2.4 Gy、G2+ 为 2.3 Gy;作者建议比较剂量分割方案时采用晚期直肠 α/β ≤ 3 Gy。

要点

  • 各晚期直肠终点 α/β 估计异质,出血最低 1.6 Gy、括约肌控制最高 3.1 Gy。
  • 频率加权平均 α/β:G1+ 2.4 Gy,G2+ 2.3 Gy。
  • 比较分割方案时建议采用晚期直肠 α/β ≤ 3 Gy。

核心结论

  • 估计了直肠放疗后多种常见晚期不良反应的 α/β 比值。
  • 比较剂量分割方案时,建议采用晚期直肠 α/β ≤ 3 Gy。

研究设计与样本

  • CHHiP 试验(ISRCTN97182923)将非转移性前列腺癌患者 1:1:1 随机至 74 Gy/37 Fr、60 Gy/20 Fr 或 57 Gy/19 Fr。
  • 分析纳入具有完整剂量学数据且基线毒性为零的患者。
  • 毒性量表合并为 6 个肠道终点:出血、腹泻、疼痛、直肠炎、括约肌控制、狭窄。
  • 采用 Lyman-Kutcher-Burman 模型(含或不含 2 Gy/Fr 等效剂量校正)按终点进行对数似然拟合以估计 α/β 比值。
  • 通过序贯纳入剂量修正因子(年龄、糖尿病、高血压、IBD/憩室病、痔疮)评估 α/β 估计敏感性,95%CI 采用 bootstrap。

主要发现

  • 无剂量修正因子时,晚期直肠 α/β 估计自出血(G1+ α/β = 1.6 Gy;95%CI 0.9-2.5 Gy)至括约肌控制(G1+ α/β = 3.1 Gy;95%CI 1.4-9.1 Gy)。
  • 肠道疼痛模型拟合差(α/β 3.6 Gy;95%CI 0.0-840 Gy)。
  • 纳入 IBD/憩室病作为剂量修正因子显著改善排便频率 G2+(P = .00041)与直肠炎 G1+(P = .00046)的拟合。
  • 无 DMF 与 DMF 模型中 α/β 比值相近:排便频率 G2+ 为 2.7 Gy vs 2.5 Gy,直肠炎 G1+ 为 2.7 Gy vs 2.6 Gy。
  • 终点 α/β 比值的频率加权平均为 G1+ α/β = 2.4 Gy、G2+ α/β = 2.3 Gy。

关键数值与推荐

  • 无 DMF 时出血 G1+ α/β = 1.6 Gy(95%CI 0.9-2.5 Gy)。
  • 无 DMF 时括约肌控制 G1+ α/β = 3.1 Gy(95%CI 1.4-9.1 Gy)。
  • 肠道疼痛 α/β = 3.6 Gy(95%CI 0.0-840 Gy),模型拟合差。
  • 频率加权平均:G1+ α/β = 2.4 Gy;G2+ α/β = 2.3 Gy。
  • 比较剂量分割方案时建议采用晚期直肠 α/β ≤ 3 Gy。

临床怎么用

  • 比较前列腺放疗不同分割方案的晚期直肠毒性时,可采用 α/β ≤ 3 Gy 进行等效剂量换算。
  • 不同晚期直肠终点(如出血与括约肌控制)的 α/β 估计存在差异,换算时需注意终点依赖性。

局限性

  • 肠道疼痛终点模型拟合差,其 α/β 估计不确定性极大(95%CI 0.0-840 Gy)。
  • α/β 估计基于 CHHiP 试验人群与特定分割方案,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Changes in fraction size of external beam radiation therapy exert nonlinear effects on subsequent toxicity. Commonly described by the linear-quadratic model, fraction size sensitivity of normal tissues is expressed by the α/β ratio. We sought to study individual α/β ratios for different late rectal effects after prostate external beam radiation therapy. METHODS AND MATERIALS: The CHHiP trial (ISRCTN97182923) randomized men with nonmetastatic prostate cancer 1:1:1 to 74 Gy/37 fractions (Fr), 60 Gy/20 Fr, or 57 Gy/19 Fr. Patients in the study had full dosimetric data and zero baseline toxicity. Toxicity scales were amalgamated to 6 bowel endpoints: bleeding, diarrhea, pain, proctitis, sphincter control, and stricture. Lyman-Kutcher-Burman models with or without equivalent dose in 2 Gy/Fr correction were log-likelihood fitted by endpoint, estimating α/β ratios. The α/β ratio estimate sensitivity was assessed using sequential inclusion of dose modifying factors (DMFs): age, diabetes, hypertension, inflammatory bowel or diverticular disease (IBD/diverticular), and hemorrhoids. 95% confidence intervals (CIs) were bootstrapped. Likelihood ratio testing of 632 estimator log-likelihoods compared the models. RESULTS: Late rectal α/β ratio estimates (without DMF) ranged from bleeding (G1 + α/β = 1.6 Gy; 95% CI, 0.9-2.5 Gy) to sphincter control (G1 + α/β = 3.1 Gy; 95% CI, 1.4-9.1 Gy). Bowel pain modelled poorly (α/β, 3.6 Gy; 95% CI, 0.0-840 Gy). Inclusion of IBD/diverticular disease as a DMF significantly improved fits for stool frequency G2+ (P = .00041) and proctitis G1+ (P = .00046). However, the α/β ratios were similar in these no-DMF versus DMF models for both stool frequency G2+ (α/β 2.7 Gy vs 2.5 Gy) and proctitis G1+ (α/β 2.7 Gy vs 2.6 Gy). Frequency-weighted averaging of endpoint α/β ratios produced: G1 + α/β ratio = 2.4 Gy; G2 + α/β ratio = 2.3 Gy. CONCLUSIONS: We estimated α/β ratios for several common late adverse effects of rectal radiation therapy. When comparing dose-fractionation schedules, we suggest using late a rectal α/β ratio ≤ 3 Gy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Brand DH, Brüningk SC, Wilkins A, et al. Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial. Int J Radiat Oncol Biol Phys. 2021. PMID: 33412260. doi:10.1016/j.ijrobp.2020.12.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。